Appreciate where you are coming from, Scooty. Not sure I necessarily agree in entirety but certainly understand your level-headed perspective.
Re "staying in your lane and leaving the science to the scientists" as such, I concur (but don't always practice what I preach... in fact, never, LOL). Our URI cell therapy science isn't what I was looking for someone to critique. I'm just curious as to other views on the company not disclosing to market and, therefore, keen on knowing where it fits within our developements (from an investment perspective), if you know what I mean. Its hard to believe that anyone would dismiss this patent application as "a little nugget of infomation". Its clearly close to being granted.... and the inventors are our people and not that of UPenn.
Its kind of a big deal considering we are patenting potentially valuable assets! Don't you consider owning IP rights by way of international patents as significant? Some biotech company's get a rerate upon the announcement of a patent granting for a drug that may treat just a handful of cancer types via a one specific cell type. The oncology industry is crying out for a universal immunetherapy platform... but you are right, lets leave the science to the scientists and let SYC explain to us in the webinar! I'm patient... but not half as patient as I was last week!!!
Enjoy... eventhough one doesn't need to understand the science:-
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023004461&_cid=P22-LDTH08-86523-1
